CD8A and neoplasm: Interestingly, the levels of tumor-infiltrating pentamer-positive CD8+ T-cells were lower in IFN-γ–treated mice compared to PBS-injected controls on day 4 post-transfer and in IL-2-injected mice compared to non-injected controls on day 14 post-transfer (Fig 1B–1C).